Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1

Interventions

nilotinib 4Cytarabine 3Filgrastim 2Cyclophosphamide 2Aprepitant 2Antilymphocyte Serum 2rasburicase 1liposomal amphotericin B 1fludarabine phosphate 1fludarabine 1bosutinib 1blinatumomab 1aldesleukin 1Water 1Voriconazole 1Urate Oxidase 1Tobacco Use Cessation Devices 1Thiotepa 1Rituximab 1Radiotherapy 1Psychiatric Rehabilitation 1Prilocaine 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Pentostatin 1Palonosetron 1Oxygen 1Interleukin-2 1Inotuzumab Ozogamicin 1Histamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia × Inotuzumab Ozogamicin × Clear all
NCT03677596 2023-11-22

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

Pfizer

Phase 4 Completed
102 enrolled 27 charts
LymphoidOther hematologic neoplasm

Leukemia, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡